Latest Pharma and Biotech News
Biotechnology
26 November 2024 US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement.
Today's issue
Refine Search
Pharmaceutical
Swiss drugmaker Idorsia was trading more than 10% higher by lunchtime on Wednesday. Idorsia earlier announced that it has entered into exclusive negotiations with an undisclosed party for the global rights to aprocitentan. 27 November 2024
Biosimilars
Samsung Bioepis has appointed Kyung-Ah Kim as its new president and chief executive, succeeding Christopher Hansung Ko, who will lead the Samsung Future Business Division. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Pharmaceutical
Japanese drugmaker Otsuka has announced the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labor and Welfare (MHLW) for the manufacture and sale in Japan of bempedoic acid - trade name Nexletol in Japan - for the treatment of hypercholesterolemia and familial hypercholesterolemia. 27 November 2024
Pharmaceutical
Berlin, Germany-based Eckert & Ziegler Radiopharma has received approval of its proprietary non-carrier added Lutetium-177 chloride, Theralugand, by the European Commission (EC). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Pharmaceutical
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) today announced that Dr Thomas Schinecker, chief executive (CEO) of Swiss pharma giant Roche (ROG: SIX), will take up the post as president of the trade association effective January 1, 2025. 26 November 2024
Pharmaceutical
US central nervous system (CNS) disorders specialist Axsome Therapeutics today released encouraging late-stage results for its narcolepsy candidate AXS-12 (reboxetine), sending its shares edging up 2.6% to $100.00 in pre-market activity. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Pharmaceutical
Shares in US biotech major Amgen were 11% lower early on Tuesday. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Biotechnology
South African-Australian private equity firm LeapFrog Investments has announced the close of its fourth fund (Fund IV), with commitments and designated co-investments totalling $1.02 billion. 26 November 2024
Biotechnology
Pyxis Oncology has announced encouraging preliminary data from a Phase I trial of PYX-201, its lead antibody-drug conjugate (ADC), in solid tumors. 26 November 2024
Biotechnology
The Phase III SKYSCRAPER-01 trial has missed its primary endpoint, Swiss cancer giant Roche has reported. 26 November 2024
Pharmaceutical
Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its investigational assets related to the HTI therapeutic HIV vaccine by US antiviral specialist Gilead Sciences. 26 November 2024
Biotechnology
US biopharma Biohaven has provided an update regarding the taldefgrobep alfa development programs in spinal muscular atrophy (SMA) and obesity. 25 November 2024
All news
Pharmaceutical
Australian Health Technology Assessment (HTA) Review Terms of Reference were released today, and will continue to advocate for bold policy reform to speed up access to innovative medicines. 22 March 2023
Biotechnology
Positive data for a new kind of cancer med, targeting the CLDN18.2 biomarker, will be presented at the March Plenary Series of the American Society of Clinical Oncology (ASCO). 22 March 2023
Generics
Even as the World Trade Organization (WTO) members continue to remain divided on the waiver of intellectual property (IP) rights for Covid-related vaccine technologies, India, South Africa, and other developing countries have resuscitated their campaign to extend the temporary waiver of IP for Covid vaccines to coronavirus drugs at the WTO. 22 March 2023
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) said today it will introduce a series of new measures, with support from partners to make it faster and easier to gain approval and to run clinical trials in the UK. 21 March 2023
Pharmaceutical
US psychiatric and neurological conditions specialist Karuna Therapeutics has announced top-line results from its Phase III EMERGENT-3 trial of its lead investigational therapy, KarXT (xanomeline-trospium) in schizophrenia. 21 March 2023
Biosimilars
Sandoz, the soon to be spun-out generics and biosimilars unit of Swiss pharma giant Novartis, today announced that the US Food and Drug Administration (FDA) approved a citrate-free high-concentration 21 March 2023
Biotechnology
US biotech Sonata Therapeutics today announced the appointment of Dr Francesco Marincola as its chief scientific officer (CSO). 21 March 2023
Generics
Zydus Lifesciences today revealed it has received final approval for Tofacitinib Tablets, 5mg and tentative approval for Tofacitinib Tablets, 10mg, generic versions of US pharma giant Pfizer’s Xeljanz from the US Food and Drug Administration (FDA). 21 March 2023
Pharmaceutical
Drugmakers have welcomed the European Commission’s commitment to a “competitiveness check,” related to the legislative environment in the region. 21 March 2023
Biotechnology
Just a couple of years ago, shares in US biotech Sangamo Therapeutics were worth more than $13, but the latest dose of bad news on the company has led them to drop below $2. 21 March 2023
Biotechnology
US biotech major Gilead Sciences has exercised its option to exclusively license Nurix Therapeutics’ investigational targeted protein degrader molecule NX 0479, with the news sending the latter’s share price up 6.5% to $9.60 by late afternoon on Monday. 21 March 2023
Pharmaceutical
Patient Voice Aotearoa’s Dr Malcolm Mulholland appeared before the Health Select Committee to voice opposition to parts of the Therapeutic Products Bill on behalf of patients in New Zealand. 21 March 2023
Pharmaceutical
A novel combination medicine designed to help people with chronic refractory gout has demonstrated a high level of efficacy in a Phase III study. 21 March 2023
Biotechnology
French pharma major Sanofi has gained another new indication approval in Europe for its already blockbuster drug Dupixent (dupilumab). 21 March 2023
Biotechnology
LEO Pharma has presented positive data on two of its pipeline assets at the American Academy of Dermatology (AAD) 2023 Annual Meeting. 20 March 2023
Biotechnology
Clinical-stage, Netherlands-based biotech company Azafaros today announced two appointments to its executive management team. 20 March 2023
Biotechnology
A few eyebrows might have been raised late last year at the size of the deal when Japanese drugmaker Takeda acquired a selective allosteric tyrosine kinase 2 (TYK2) inhibitor from privately-held US drug discovery company Nimbus Therapeutics. 20 March 2023
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Lynparza (olaparib) for use as combination therapy with abiraterone and prednisone or prednisolone, for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. 20 March 2023
Biotechnology
Patient advocacy groups have expressed regret at Janssen’s decision to hit the pause button on its UK launch of Carvykti (ciltacabtagene autoleucel). 20 March 2023
Biotechnology
The UK’s National Institute for Health and Care Excellence (NICE) has issued a final decision recommending the use of Oxlumo (lumasiran) on the National Health Service (NHS) in England as an option for treating primary hyperoxaluria type 1 (PH1) in people of all ages, US RNAi therapy specialist Alnylam Pharmaceuticals (Nasdaq: ALNY) announced today. 20 March 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze